234 related articles for article (PubMed ID: 30761753)
1. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
3. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.
Krause A; Aries PM; Berger S; Fiehn C; Kellner H; Lorenz HM; Meier L; Müller GA; Müller-Ladner U; Schwarting A; Tony HP; Peters MA; Wendler J
Z Rheumatol; 2019 Nov; 78(9):881-888. PubMed ID: 30276727
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
[TBL] [Abstract][Full Text] [Related]
7. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
9. A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.
Stradner MH; Dejaco C; Brickmann K; Graninger WB; Brezinschek HP
Arthritis Res Ther; 2016 Aug; 18(1):190. PubMed ID: 27558631
[TBL] [Abstract][Full Text] [Related]
10. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
[TBL] [Abstract][Full Text] [Related]
11. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
12. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
16. Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.
Son KM; Lee SY; Seo YI; Choi JE; Kim HA
Clin Rheumatol; 2017 Jun; 36(6):1221-1227. PubMed ID: 28451869
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
18. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
20. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab.
Sargin G; Senturk T; Yavasoglu I; Kose R
Int J Rheum Dis; 2018 Dec; 21(12):2122-2127. PubMed ID: 30338636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]